Exhibit 99.3

 Post-ASCO Conference CallInterim Data Review  JUNE 8, 2021 

 2  Forward-Looking Statements  This presentation contains forward-looking statements about PDS Biotechnology Corporation (“PDSB”), and its businesses, business prospects, strategies and plans, including but not limited to statements regarding anticipated pre-clinical and clinical drug development activities and timelines and market opportunities. All statements other than statements of historical facts included in this presentation are forward-looking statements. The words “anticipates,” “may,” “can,” “plans,” “believes,” “estimates,” “expects,” “projects,” “intends,” “likely,” “will,” “should,” “to be,” and any similar expressions or other words of similar meaning are intended to identify those assertions as forward-looking statements. These forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those anticipated.Factors that may cause actual results to differ materially from such forward-looking statements include those identified under the caption “Risk Factors” in the documents filed with the Securities and Exchange Commission (“SEC”) from time to time, including its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. Except to the extent required by applicable law or regulation, PDSB undertakes no obligation to update the forward-looking statements included in this presentation to reflect subsequent events or circumstances. 

   3    PDS Biotech’s Versamune®-based immunotherapies are designed to promote a powerful in vivo tumor-specific CD8+ killer T-cell response  Generate the right type and quantity of effective CD8+ killer T-cells  Generate potency without systemic side effects  Generate memory T-cells, to enhance durability of response     A significant barrier to effective immunotherapy has been the inability to promote adequate CD8+ killer T-cell responses in vivo resulting in diminished efficacy; 70-90% of cancer patients fail check point inhibitor therapy   Versamune®-based therapies also show promising potential to: 

 The PDS0101 triple combination is being evaluated in advanced HPV-positive checkpoint inhibitor (CPI) naïve and CPI refractory patients  4    Checkpoint inhibitor naïve  Checkpoint inhibitor refractory  Description  Patients have failed chemotherapy and radiation treatment  Patients have failed chemotherapy, radiation and checkpoint inhibitor therapy  Standard of care  Checkpoint inhibitors  Few options – usually another checkpoint inhibitor treatment  Percentage of patients who have an objective response  12-24%  5-12%  Historical median survival  7-11 months  3-4 months  Options after treatment failure  Patients are now CPI refractory  Extremely limited  Objective response is defined as a tumor reduction of >30% as measured by RECIST 1.1 

 PDS0101 is developed to treat cancers caused by Human papillomavirus (HPV)16 infectionCombines the Versamune® technology with proprietary modified proteins from the HPV16 viral protein that is expressed by or contained in the HPV16-positive cancersThe interim data suggest that PDS0101 may be effective in promoting the induction of tumor-attacking HPV16-specific killer T-cells resulting in tumor reductionThe interim data suggest that PDS0101 may be associated with clinically meaningful responses in patients with advanced HPV-associated cancerThe interim data suggest that the design of immunotherapeutic combinations including polyfunctional CD8+ (killer) and CD4+ (helper) T-cell activating immunotherapies may present the potential for powerful anti-tumor clinical efficacy  PDS0101 is designed to efficiently induce polyfunctional (potent) CD8+ killer T-cells in-vivo that recognize cancers caused by HPV Type 16   5  Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies. Presented at: American Society of Clinical Oncology 2021 Annual Meeting; June 4-8, 2021; Virtual. Abstract: 2501.  

 6  Bintrafusp alfa (bi-functional checkpoint inhibitor)  Tumor Regression: 0/16 (0%)T-cell Clones: 22  PDS0101 + Bintrafusp alfa + M9241  Tumor Regression: 13/17 (76%)T-cell Clones: 3  *Reference: Smalley Rumfield C, Pellom ST, Morillon II YM, et al; Journal for ImmunoTherapy of Cancer 2020; 8:e000612. doi: 10.1136/jitc-2020-000612  Preclinical study: Triple combination of PDS0101, Bintrafusp alfa (M7824) and M9241 (NHS-IL12) demonstrated higher targeted T-cell response  Red – CD8+ (killer) T-cellsGreen – CD4 + (helper) T-cells  T-cell clones per 25% of TCR repertoire (Average)  Combination of PDS0101 with Bintrafusp alfa or M9241 generated superior targeted T-cell response; triple combination demonstrated superior efficacy     

   PDS0101 is used in combination with other immunotherapies resulting in a multifunctional therapy  7  Bintrafusp alfa exposes the tumor to attack and M9241 issues a signal calling T-cells to the tumor  Reference: Smalley Rumfield C, Pellom ST, Morillon II YM, et al; Journal for ImmunoTherapy of Cancer 2020; 8:e000612. doi: 10.1136/jitc-2020-000612      Bintrafusp ALFA  M9241                        PDS0101 induces a powerful, HPV16-targeted CD8+ and CD4+ T-cell response  PDS0101  Activated CD8+ killer T-cell  Activated CD4+ helper T-cell  The triple combination works in synergy to prompt targeted T-cells to infiltrate and destroy the tumor  TUMOR DESTROYED 

 PHASE 2 TRIAL OF PDS0101 + BINTRAFUSP ALFA + NHS-IL12 INTERIM CLINICAL DATA(L. V. Wood) 

 Phase 2 NCI-led clinical trial evaluating the triple combination of PDS0101, Bintrafusp alfa and M9241 in advanced HPV-associated cancer  9  Indication  Patients with advanced HPV-associated cancer who have failed prior treatment  Clinical Agents  Bintrafusp alfa: Bifunctional “trap” fusion proteinM9241: Antibody-conjugated immuno-cytokinePDS0101: Versamune®-based immunotherapy generating HPV-specific CD8+ T-cells  Study goals  Group 1: Objective response rate (ORR) in checkpoint inhibitor (CPI) naïve patientsGroup 2: ORR in patients who have failed checkpoint inhibitor therapy (CPI refractory)  Timing  Full enrollment of 56 patientsComplete enrollment expected by Q1 2022  Trial Sponsor    The objective of this trial is to confirm that PDS0101 enhances the therapeutic benefit of Bintrafusp alfa and M9241 and may lead to expanded evaluation in several pipeline products 

 Percentages of HPV-related cancers (anal, cervical, head and neck, vaginal and vulvar cancers) included in the study population  Most HPV-associated cancers are represented in interim data from NCI-led Phase 2 trial - >95% of all US cases  10  Cervical10 (40%)  Anal6 (24%)  Vaginal/Vulvar3 (12%)  Head & Neck6 (24%)  Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies. Presented at: American Society of Clinical Oncology 2021 Annual Meeting; June 4-8, 2021; Virtual. Abstract: 2501.   * These numbers reflect data as of evaluation of 25 patients; numbers will change as more patients undergo evaluation 

 As of March 1, 2021, 25 patients had received the triple combination of PDS0101, M9241 and Bintrafusp alfa The median follow-up has been 8 months  Study enrolled a challenging patient population: 96% had failed both chemotherapy and radiation treatment; 56% had also failed checkpoint inhibitor therapy  11    All patientsN=25*  Age, median (range), years  50 (37-80%)  Female, n (%)  17 (68%)  Number of prior anticancer therapies, n (%) 1 2 ≥3  5 (20%)11 (44%)9 (36%)  Prior chemotherapy, n (%)  25 (100%)  Prior radiotherapy, n (%)  24 (96%)  Prior immunotherapy, n (%)  14 (56%)  HPV status, n (%) HPV 16 positive HPV 16 negative Negative  18 (72%)7 (28%)1 (4%)  Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies. Presented at: American Society of Clinical Oncology 2021 Annual Meeting; June 4-8, 2021; Virtual. Abstract: 2501.   * These numbers reflect data as of evaluation of 25 patients; numbers will change as more patients undergo evaluation 

 Triple combination achieved 83% objective response among 6 HPV16-positive checkpoint inhibitor naive patients, suggesting potential efficacy  12  Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies. Presented at: American Society of Clinical Oncology 2021 Annual Meeting; June 4-8, 2021; Virtual. Abstract: 2501.   * These numbers reflect data as of evaluation of 25 patients at a median of 8 months; numbers will change as more patients undergo evaluation 

 13  Triple combination shows promising durability in HPV16-positive checkpoint inhibitor naïve patients, suggesting potential efficacy    PDS0101 + Bintrafusp alfa + M9241  Standard of Care(Checkpoint Inhibitors)    HPV16-positive    Number of subjects  6    Ongoing responses at median of 8 months  80% (4/5)1 patient came off combination halting response    Survival at median of 8 months  100% (6/6)  Historical is 7-11 months  Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies. Presented at: American Society of Clinical Oncology 2021 Annual Meeting; June 4-8, 2021; Virtual. Abstract: 2501.   Preliminary results suggest PDS0101 induction of in vivo highly active tumor-attacking HPV16 killer (CD8+) T-cells that have the potential for effective disease reduction and ongoing responses  * These numbers reflect data as of evaluation of 25 patients; numbers will change as more patients undergo evaluation 

 Triple combination achieved 58% tumor reduction among 12 HPV16 checkpoint inhibitor refractory patients  14  Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies. Presented at: American Society of Clinical Oncology 2021 Annual Meeting; June 4-8, 2021; Virtual. Abstract: 2501.   * These numbers reflect data as of evaluation of 25 patients at a median of 8 months; numbers will change as more patients undergo evaluation  50% (2/4) recently added patients already have ongoing tumor reduction but have not yet attained ORRTumor reduction is consistent with first 8 patients showing tumor reduction in 5/8 

 15  Triple combination shows promising durability in HPV16-positive checkpoint refractory patients    PDS0101 + Bintrafusp alfa + M9241HPV16 positive  Standard of Care(Checkpoint Inhibitors)  Number of patients  12    Number of patients with ongoing tumor reduction at a median of 8 months  86% (6/7)    Number of patients with ongoing objective response at a median of 8 months  80% (4/5)1 patient came off combination halting response    Survival at median of 8 months  83% (10/12)  Historical is 3-4 months  Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies. Presented at: American Society of Clinical Oncology 2021 Annual Meeting; June 4-8, 2021; Virtual. Abstract: 2501.   * These numbers reflect data as of evaluation of 25 patients; numbers will change as more patients undergo evaluation  Preliminary results suggest PDS0101 induction of in vivo highly active tumor-attacking HPV16 killer (CD8+) T-cells even in extensively treated and immunologically limited patients have the potential for effective disease reduction and ongoing responses 

 Results in seven (7) HPV16-negative patients suggests critical role of PDS0101-induced HPV16-specific CD8+ T-cells in promoting tumor reduction  16  Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies. Presented at: American Society of Clinical Oncology 2021 Annual Meeting; June 4-8, 2021; Virtual. Abstract: 2501.   * These numbers reflect data as of evaluation of 25 patients; numbers will change as more patients undergo evaluation  Preliminary results suggest that HPV16-specific CD8+ and CD4+ T-cell induction by PDS0101 as predicted by preclinical studies may promote enhanced clinical benefit of the triple combination 

 Results in seven (7) HPV16-negative patients suggests critical role of PDS0101-induced CD8+ T-cells in promoting survival  17  Observation of survival in patients with HPV16-positive cancer relative to those patients with HPV16-negative cancer highlights the critical role of PDS0101 in the triple combination  Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies. Presented at: American Society of Clinical Oncology 2021 Annual Meeting; June 4-8, 2021; Virtual. Abstract: 2501.   * These numbers reflect data as of evaluation of 25 patients at a median of 8 months; numbers will change as more patients undergo evaluation 

 Adverse Event Summary  All patientsN=25*    Grade ≥2   Treatment-related adverse events (TRAEs)  23 (92%)  TRAEs leading to discontinuation of ≥ 1 drug(s)  5 (20%)  Treatment-related serious AEs  7 (28%)  TRAEs in ≥5% of patients    Anemia  12 (48%)  Lymphocyte decrease  7 (28%)  Flu like symptoms  6 (24%)  Injection site reactions  5 (20%)  Hematuria  4 (16%)  AST/ ALT/ Alk phos elevation  4 (16%)  Keratoacanthomas  4 (16%)  Leukocyte decrease  3 (12%)  Maculopapular rash  3 (12%)  Pruritis  3 (12%)  Nausea/ vomiting   3 (12%)  Mucositis  3 (12%)  Hypothyroidism  3 (12%)  Peripheral motor neuropathy  2 (8%)  Fatigue  2 (8%)  PDS0101 does not appear to compound toxicities to the triple combination therapyDocumented adverse events with the triple combination are consistent with those previously observed with Bintrafusp alfa and M9241Grade 3 TRAEs occurred in 10 (40%) patientsAnemia due to gross hematuria (n=4), AST/ALT elevation (n=2); flu like symptoms (n=1), nausea/ vomiting (n=1), leukopenia (n=1), lymphopenia (n=2), HLH (n=1)One patient with transient grade 3 leukopenia and lymphopenia also had transient grade 4 neutropenia4 patients who originally had grade 3 toxicities with the triple combo including M9241 at 16.8 mcg/kg tolerated the triple combo with M9241 at 8 mcg/kg w/o any further grade ≥3 toxicitiesNo treatment-related deaths occurred  No new or elevated toxicities observed from the addition of PDS0101 to the combination; PDS0101 only caused transient injection site reactions  18  Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies. Presented at: American Society of Clinical Oncology 2021 Annual Meeting; June 4-8, 2021; Virtual. Abstract: 2501.   * These numbers reflect data as of evaluation of 25 patients; numbers will change as more patients undergo evaluation 

 REVIEW OF KEY FINDINGS ANDIMPLICATIONS FOR PDS BIOTECH(F. Bedu-Addo)  

 PDS0101 + KEYTRUDA® (VERSATILE-002): First line treatment of recurrent/metastatic HPV16-positive head and neck cancerPDS0101 highly active in promoting HPV16-specific T-cells even in advanced cancer patientsPatients treated earlier in disease recurrence may be “relatively healthier” with even higher potential for clinical benefitKEYTRUDA ® monotherapy results in ORR in 20% of patients PDS0101 + Chemoradiotherapy (IMMUNOCERV): Locally advanced cervical cancerMD Anderson independent studies suggest that patients with HPV-specific T-cells may have improved clinical outcomes  Evidence of PDS0101 in vivo HPV16-specific CD8+ T-cell induction has direct implications for potential efficacy in ongoing Phase 2 trials  20    PDS0101’s ability to promote in vivo induction of potent HPV16-specific T-cells presents strong promise for all ongoing studies 

 Tumor reduction occurred in 67% (12/18) of all patients including both CPI naïve and CPI refractory patients who had HPV16-positive cancerCPI naïve diseaseTumor reduction in 83% (5/6) of patientsObjective response (ORR) in 83% (5/6) of patients with 1 achieving a complete response100% (6/6) alive at median 8 months compared to historical median survival of 7-11 monthsCPI refractory diseaseTumor reduction in 58% (7/12) of patients Objective response (ORR) already achieved in 42% (5/12) patients with 1 achieving a complete response83% (10/12) alive at median 8 months compared to historical median survival of 3-4 months  Combination therapy with PDS0101 demonstrates evidence of notable clinical activity for patients with advanced treatment refractory HPV16-postitive cancer  21    Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies. Presented at: American Society of Clinical Oncology 2021 Annual Meeting; June 4-8, 2021; Virtual. Abstract: 2501.   * These numbers reflect data as of evaluation of 25 patients; numbers will change as more patients undergo evaluation  CONCLUSION: 89% (16/18) of all HPV16-positive patients with CPI naïve and CPI refractory advanced disease are alive at a median 8 months of follow up 

 APPENDIX: 2021 ASCO Presentation 

 Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies  Julius Strauss1, Charalampos S. Floudas2, Houssein Abdul Sater2, Michell Manu3, Elizabeth Lamping2, Deneise C Francis2, Lisa M Cordes2, Jenn Marte2, Renee N Donahue1, Caroline Jochems1, Jason Redman2, Ravi A Madan2, Marijo Bilusic2, Fatima Karzai2, Scott Norberg2, Christian S. Hinrichs2, Lauren V Wood4, Frank K Bedu-Addo4, Jeffrey Schlom1, James L Gulley21Laboratory of Tumor Immunology and Biology, NCI; 2Genitourinary Malignancies Branch, NCI; 3Leidos Biomedical Research, Inc.; 4PDS Biotechnology, Princeton, NJ  Abstract No. 2501. Presented at the 2021 ASCO Annual Meeting, June 4–8, 2021; Virtual. Presentation No. 

 25  J. Strauss  Introduction  >630,000 new cases of HPV-related cancer (e.g. cervical, oropharyngeal, anal) reported worldwide annually1PD-1 inhibitors have been evaluated in these tumor types and ORRs have ranged from 13–24%2-8Nivolumab & pembrolizumab are FDA approved for HNSCC; pembrolizumab is approved for PD-L1+ cervical cancerUnfortunately, the majority of patients who receive these anti PD-1 inhibitors will progress For these patients with checkpoint refractory disease there is no clear effective standard of care therapyHPV infection is also linked to upregulation of TGF-β signaling9Genome-wide association studies showed that TGF-βR1 is significantly overexpressed in HPV-related cancer10  1. de Martel C, et al. Int J Cancer. 2017;141:664–70; 2. Viens LJ, et al. MMWR Morb Mortal Wkly Rep.; 2. Bauml J, et al. J Clin Oncol 2017;35:1542–49; 3. Ott PA, et al. Ann Oncol. 2017;28:1036–41; 4. Hollebecque A, et al. J Clin Oncol. 2017;35(Suppl):Abstract 5504; 5. Chung HC, et al. J Clin Oncol. 2018;36(Suppl):Abstract 5522; 6. Ferris RL, et al. N Engl J Med. 2016;375:1856–67; 7 Mehra R, et al. Br J Cancer. 2018;119:153–59; 8 Morris VK, et al. Lancet Oncol. 2017;18:446–53. 2016;65:661–66; 9. Torres-Poveda K, et al. World J Clin Oncol. 2014;5:753-63; 10. Levovitz C, et al. Cancer Res. 2014;74:6833-44.  

 J. Strauss  Bintrafusp alfa: a TGF-β and PD-L1 Inhibitor  Bintrafusp alfa is an innovativefirst-in-class bifunctional fusion protein composed of the extracellular domain of the TGF-βRII receptor (a TGF-β “trap”) fused to a human IgG1 mAb blocking PD-L1In a phase 1 study, Bintrafusp alfa was well tolerated and produced durable responses in several solid tumor types 1-3  1.Strauss J, et al. Clin Cancer Res. 2018;24:1287–95; 2. Paz-Ares L, et al. J Clin Oncol. 2018;36(Suppl):Abstract 9017; 3. Cho BC, et al. Ann Oncol. 2018;29(Suppl):Abstract 1048O..   26 

 J. Strauss  Bintrafusp alfa in HPV-Related Cancers  1.Strauss J, et al. J Immunother Cancer. 2020 Dec;8(2):e001395.  . 2020 Dec;8(2):e001395   . 2020 Dec;8(2):e001395   . 2020 Dec;8(2):e001395.   79 patients with advanced HPV-associated cancers (59 checkpoint naïve and 20 checkpoint refractory) received Bintrafusp alfa IV every 2 weeks until disease progression or intolerance1Side effect profile similar to standard anti-PD(L)1 inhibitors with the addition of keratoacanthomas & mucosal bleeding ORR was 30.5% in checkpoint naïve diseaseORR was 10% in checkpoint refractory disease  27 

 J. Strauss  PDS0101: Versamune®-based HPV 16 cancer vaccine  Micellar multi-peptide based therapeutic vaccine targeting HPV 16 E6/ E7 (HPV 16 is the genotype responsible for majority of HPV-related cancers worldwide)Versamune® nanoparticles contain the cationic lipid R-DOTAP which upregulates type I IFNs and promotes antigen cross-presentation In a phase I trial patients with cervical intraepithelial neoplasia developed strong HPV-specific CD4+ and CD8+ T cell immune responses1 Was well tolerated with mild transient site reactions and minimal systemic toxicity  28  1.Wood LV, et al., SITC 2019, (O19) Abstract ID 12533. 

 J. Strauss  M9241 (NHSIL12)  Tumor targeting IL12 immunocytokineComposed of two IL12 heterodimers fused to NHS76 antibody which binds to histones on free DNA fragments found in areas of tumor necrosisIn phase 1 trial in patients with advanced solid tumors the most frequently observed AEs included flu like symptoms and asymptomatic lab abnormalities (e.g. mild cytopenias and liver enzyme elevations) 1M9241 treatment resulted in increased T cell infiltration in the TME  1.Strauss J, et al. Clin Cancer Res. 2019 Jan 1;25(1):99-109.  . 2019 Jan 1;25(1):99-109     29 

 Preclinical Studies with PDS0101 + NHSIL12 + M7824  30  Preclinical Combo of PDS0101, M9241 & Bintrafusp alfa   Single, double and triple combinations were evaluated in a TC-1 HPV16+ tumor modelTriple combination generated the maximum HPV-specific immune response, T cell infiltration in the TME and tumor reduction1  1.Rumfield C, J Immunother Cancer. 2020 Jun;8(1):e000612.  30 

 J. Strauss  Study Design  Patients with advanced HPV-related cancers received the combination of Bintrafusp alfa at 1200 mg flat dose i.v. q 2wks, M9241 at 16.8 mcg/kg s.c. q 4 wks and PDS0101 given as two separate 0.5 ml s.c. injections q 4 wks [NCT04287868]Dose reductions of M9241 to 8 mcg/kg were allowed as well as skipped doses of agent(s) for toxicitiesHPV genotyping was done with PCR based assays (BD Onclarity or Molecular MD) if testing not already done   PopulationCervicalAnalP16+ oropharyngealOther HPV-associated   EndpointsPrimary: ORRSecondary: safety  Treatment until confirmed progression, unacceptable toxicity, or any criteria for withdrawal; treatment past progression was allowed     31 

 J. Strauss  Results  Key baseline patient and disease characteristicsAs of 01 MAR 2021, 25 patients had received the triple combination of PDS0101, M9241 & Bintrafusp alfa The median follow-up is 8 months    All patientsN=25  Age, median (range), years  50 (37-80)  Female, n (%)  17 (68)  Tumor type, n (%) Cervical Anal Head & Neck SCC Vulvar/ Vaginal  10 (40)6 (24)6 (24)3 (12)  Number of prior anticancer therapies, n (%) 1 2 ≥3  5 (20)11 (44)9 (36)  Prior chemotherapy, n (%)  25 (100)  Prior radiotherapy, n (%)  24 (96)  Prior PD-(L)1 inhibitor therapy, n (%)  14 (56)  HPV status, n (%) HPV 16 HPV type other than 16 Negative  18 (72)6 (24)1 (4)  32 

 J. Strauss  Results  Safety summaryGrade 3 TRAEs occurred in 10 (40%) patientsanemia due to hematuria (n=4), AST/ALT elevation (n=2); flu like symptoms (n=1), nausea/ vomiting (n=1), leukopenia (n=1), lymphopenia (n=2), HLH1 (n=1)All four patients with grade 3 hematuria had cervical ca with prior pelvic RT + brachytherapyOne patient with transient grade 3 leukopenia and lymphopenia also had transient grade 4 neutropenia4 patients who originally had grade 3 toxicities with the triple combo including M9241 at 16.8 mcg/kg tolerated the triple combo with M9241 at 8 mcg/kg w/o any further grade ≥3 toxicitiesNo treatment-related deaths occurred    All patientsN=25    Grade ≥2   Treatment-related adverse events (TRAEs)  23 (92)  TRAEs leading to discontinuation of ≥ 1 drug(s)  5 (20)  Treatment-related serious AEs  7 (28)  TRAEs in ≥5% of patients    Anemia  12 (48)  Lymphocyte decrease  7 (28)  Flu like symptoms  6 (24)  Injection site reactions   5 (20)  Hematuria  4 (16)  AST/ ALT/ Alk phos elevation  4 (16)  Keratoacanthomas  4 (16)  Leukocyte decrease   3 (12)  Maculopapular rash  3 (12)  Pruritis  3 (12)  Nausea/ vomiting   3 (12)  Mucositis  3 (12)  Hypothyroidism  3 (12)  Peripheral motor neuropathy  2 (8)  Fatigue  2 (8)  1. Hemophagocytic lymphohistiocytosis   33 

 J. Strauss  Results    All patientsN=25  HPV 16+N=18  HPV 16+ CPI Naïve N=6   HPV 16+ CPI RefractoryN=12  BOR, n (%) Complete response (CR) Partial response (PR)  2 (8)8 (32)  2 (11.1)8 (44.4)  1 (16.7)4 (66.7)  1 (8.3)4 (33.3)  ORR (CR+PR), n (%)   10 (40)  10 (55.6)  5 (83.3)  5 (41.7)  Disease Reduction, n (%)  13 (52)  12 (66.7)  5 (83.3)  7 (58.3)  Ongoing response, n/n (%)   8/10 (80)  8/10 (80%)  4/5 (80%)  4/5 (80%)  Overall Survival, n/n (%)*  20/25 (80)  16/18 (88.9)  6/6 (100)  10/12 (83.3)  1. Bauml J, et al. J Clin Oncol 2017;35:1542–49; 2. Ott PA, et al. Ann Oncol. 2017;28:1036–41; 3. Mehra R, et al. Br J Cancer. 2018;119:153–59; 4. Ferris RL, et al. N Engl J Med. 2016;375:1856–67; 5. Morris VK, et al. Lancet Oncol. 2017;18:446–53; 6. Chung HC, et al. J Clin Oncol 2019;37: 1470-8; 7. Strauss J, et al. J Immunother Cancer. 2020 Dec;8(2):e001395  J Clin Oncol 2019;37:1470–8   J Clin Oncol 2019;37:1470–8   J Clin Oncol 2019;37:1470–8   J Clin Oncol 2019;37:1470–8   34  * Median 8 months of follow up  Patient OutcomesORR 55.6% (tumor reduction 66.7%) in HPV 16+ diseaseORR 83.3% in CPI naïve HPV 16+ diseaseORR 41.7% (tumor reduction 58.3%) in CPI refractory HPV 16+ disease After a median 8 months of follow up:80% of responses are ongoing6/6 (100%) pts with HPV 16+ CPI naïve disease remain alive (historical median OS is 7-11 mo)1-6 10/12 (83.3%) pts with HPV 16+ CPI refractory disease remain alive (historical median OS is 3-4 mo) 7 

 J. Strauss  Results  Responses in HPV 16+ disease occurred irrespective of tumor type  35 

 J. Strauss  Results  Overwhelming majority of HPV 16+ CPI naive pts had a responseMajority of HPV 16+ CPI refractory pts had tumor shrinkage   Primary Refractory: Prior PD or SD < 6 months Secondary Refractory: Prior PR or SD > 6 months  36 

 J. Strauss  Conclusions  Triple combination of PDS0101, M9241 and Bintrafusp alfa appears to have a manageable safety profile along with early evidence of notable clinical activity for pts with advanced HPV 16+ malignanciesClinical activity noted irrespective of tumor type or CPI statusORR was 55.6% (tumor reduction 66.7%) in all pts with advanced HPV 16+ diseaseORR was 83.3% in patients with CPI naive HPV 16+ disease ORR was 41.7% (tumor reduction 58.3%) in patients with CPI refractory HPV 16+ diseaseAfter a median 8 months of follow up:80% of responses are ongoing6/6 (100%) pts with HPV 16+ CPI naïve disease remain alive10/12 (83.3%) pts with HPV 16+ CPI refractory disease remain alive Accrual is ongoing to the triple combination [NCT04287868]  37 

 J. Strauss  Acknowledgments  The authors would like to thank the patients and their familiesFunding for the trial was provided by the Center for Cancer Research, National Cancer Institute, and National Institutes of Health Clinical CenterM9241 and Bintrafusp alfa were provided by Merck KGaA, Darmstadt, GermanyPDS0101 was provided by PDS Biotechnology, Florham Park, NJ Correspondence: Julius Strauss julius.strauss@nih.gov  38